Bristol-Myers Squibb Company

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

BMY

Financials

Bristol-Myers Squibb Company

Noticias

Wall Street Lunch: Netflix Draws Bullish Backing As Ad Revenue Seen Doubling To $3B

Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside (RVMD)

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

Big Pharma Is Thinking Small on Deals. That’s a Boon for Biotech.

Potential $5,000 Monthly Income: 12 Investments To Buy And Hold For The Next 10 Years

BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?

Why Is Replimmune Stock Sinking Friday? - Replimune Group (NASDAQ:REPL)

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

Bristol-Myers Squibb Earnings Preview: What to Expect

Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts